Skip to main content Accessibility help

Evaluation of an Intervention Designed to Decrease the Rate of Nosocomial Methicillin-Resistant Staphylococcus aureus Infection by Encouraging Decreased Fluoroquinolone Use

  • Karl J. Madaras-Kelly (a1), Richard E. Remington (a2), Pamela G. Lewis (a3) and Dennis L. Stevens (a3) (a4)



Society for Health Care Epidemiology guidelines recommend decreasing the use of fluoroquinolone antibiotics in institutions where methicillin-resistant Staphylococcus aureus (MRSA) is endemic. We evaluated whether an intervention to limit fluoroquinolone use was associated with a lower rate of nosocomial MRSA infection and summarized changes in antibiotic use, changes in other variables potentially correlated with a lower rate of MRSA infection, and rates of nosocomial infections due to other pathogens.


Single-center quasi-experimental design. A time series of nosocomial MRSA infections was measured at monthly intervals from July 2001 through June of 2004; there were 80 MRSA infections recorded. Segmented regression analysis (ie, quasi-Poisson generalized linear models) was used to evaluate variables possibly associated with the nosocomial MRSA infection rate.


An 87-bed Veterans Affairs teaching hospital with an extended-care facility.


A physician-directed computer-generated intervention designed to limit the use of fluoroquinolone antibiotics was initiated, and institutional changes in antibiotic use and nosocomial MRSA infection rates were tracked.


After the intervention, fluoroquinolone use decreased by approximately 34%, and levofloxacin use decreased by approximately 50%. Decreased fluoroquinolone use was offset by increased cephalosporin, piperacillin-tazobactam, and trimethoprim-sulfamethoxazole use. The nosocomial MRSA infection rate decreased from 1.37 to 0.63 episodes per 1,000 patient-days after the study intervention (P = .02). Coagulase-negative Staphylococcus and Enterococcus infection rates also decreased. However, the rate of infection with gram-negative organisms increased. The rate of MRSA infection was positively correlated with levofloxacin use (P = .01) and azithromycin use (P = .08), whereas it was negatively correlated with summer season (P = .05). In a subsequent model, the rate of MRSA infection was negatively correlated with the study intervention (P = .04).


Reduction in the institutional use of fluoroquinolones may be associated with a lower nosocomial MRSA infection rate.


Corresponding author

ISU College of Pharmacy, c/o Boise VA Medical Center, 500 West Fort Street (119A), Boise, ID 83702 (


Hide All
1.Weber, SG, Gold, HS, Hooper, DC, Karchmer, AW, Carmeli, Y. Fluoroquinolones and the risk of methicillin resistant Staph aureus in hospitalized patients. Emerg Infect Dis 2003; 9:14151422.
2.Graffunder, EM, Venezia, RA. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother 2002; 49:9991005.
3.Hori, S, Sunley, R, Tami, A, Grundmann, H. The Nottingham Staphylococcus aureus population study: prevalence of MRSA among the elderly in a university hospital. J Hosp Infect 2002; 50:2529.
4.Monnet, DL, MacKenzie, FM, Lopez-Lozano, JM, et al. Antimicrobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 1996-2000. Emerg Infect Dis 2004; 10:14321441.
5.Crowcroft, NS, Ronveaux, O, Monnet, DL, Mertens, R. Methicillin-resistant Staphylococcus aureus and antimicrobial use in Belgian hospitals. Infect Control Hosp Epidemiol 1999; 20:3136.
6.Dziekan, G, Hahn, A, Thune, K. Methicillin-resistant Staphylococccus aureus in a teaching hospital: investigation of nosocomial transmission using a matched case-control study. J Hosp Infect 2000; 46:263270.
7.Harbarth, S, Liassine, N, Dharan, S, Herrault, P, Auckenthaler, , Pittet, D. Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2000; 31:13801385.
8.Manhold, C, von Rolbieki, U, Brase, R, et al. Outbreaks of Staphylococcus aureus infections during treatment of late onset pneumonia with ciprofloxacin in a prospective randomized study. Intensive Care Med 1998; 24:13271330.
9.McDonald, LC, Lauderdale, TL, Lo, RJ, Tsai, JJ, Hung, CC. Colonization of HIV infected outpatients in Tiawan with methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Int J STD AIDS 2003; 14: 473477.
10.Johnson, CK, Polk, RE, Edmond, M, Wenzel, R. Trends in antimicrobial use from 1999 to 2001 in 36 US hospitals: a SCOPE-MMIT report. In: Program and abstracts of the 42nd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002; San Diego, CA. Abstract K-1005.
11.Muto, CA, Jernigan, JA, Ostrowsky, BE, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol 2003; 24:362378.
12.Niederman, MS, Mandell, LA, Anzueto, A, et al. The American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163:17301754.
13.Bartlett, JG, Gorbach, SL. Treatment of aspiration pneumonia and primary lung abscess: penicillin G vs clindamycin. JAMA 1975; 234:935937.
14.Marik, PE. Aspiration pneumonitis and aspiration pneumonia. New Engl J Med 2001; 344:665667.
15.Fagon, JY, Chastre, J, Wolff, M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia: a randomized trial. Ann Intern Med 2000; 132:621630.
16.Chan, R, Hemeryck, L, O'Regan, M, Clancy, L, Feely, J. Oral versus intravenous antibiotics for community acquired lower respiratory tract infection in a general hospital: open, randomised controlled trial. BMJ 1995;310:13601362.
17.Dewan, NA, Rafique, S, Kanwar, B, et al. Acute exacerbation of COPD: factors associated with poor treatment outcome. Chest 2000; 117:662671.
18.Baron, TH, Morgan, DE. Acute necrotizing pancreatitis. New Engl J Med 1999; 340:14121417.
19.Harris, A, Bradham, D, Baumgartner, M, et al. The use and interpretation of quasi-experimental design in infectious diseases. Clin Infect Dis 2004; 38:15861591.
20.Anon, . National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990–May 1999, issued June 1999. Am J Infect Control 1999; 27:520532.
21.Hartstein, A, Mullingan, MW. Methicillin. In: Mayall, CG, ed. Resistant Staphylococcus aureus in hospital epidemiology and infection control. 2nd ed. Philadelphia: Lippincott, Williams & Wilkins; 1999.
22.Cooper, BS, Stone, SP, Kibbler, CC. Systematic review of isolation policies in the hospital management of methicillin-resistant Staphylococcus aureus: a review of the literature with epidemiological and economic modeling. Health Technology Assessment 2003; 7:1139.
23.World Health Organization Collaborating Center for Drug Statistics Methodology Web site. Available at: Accessed August 4, 2004.
24.NCCLS. Performance standards for antimicrobial susceptibility testing. Wayne, PA: NCCLS; 2004. NCCLS document M100-S14.
25.Neter, J, Kutner, MH, Wasserman, W, Nachtsheim, CJ, Neter, J. Applied linear statistical models. 4th ed. New York, NY: McGraw-Hill/Irwin; 1996.
26.McCullagh, P, Neider, JA. Generalized linear models. 2nd ed. Boca Raton, FL: Chapman & Hall/CRC; 1989.
27.R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. Available at: Accessed March 10, 2004.
28.Ansari, F, Kirsteen, G, Nathawani, D, et al. Outcome of an intervention to improve hospital antibiotic prescribing: interrupted time series with segmented regression analysis. J Antimicrob Chemother 2003; 52:842848.
29.Ramsay, C, Brown, E, Hartman, G, Davey, P. Room for improvement: a systematic review of the quality of evaluations of interventions to improve hospital antibiotic prescribing. J Antimicrob Chemother 2003; 52: 764771.
30.The Cochrane Effective Practice and Organization of Care Group (EPOC). The data collection checklist (2002). Cochrane EPOC methods papers. Available at: Accessed November 15, 2003.
31.Farr, BM. Nosocomial infections related to use of intravascular devices inserted for short-term vascular access in hospital epidemiology and infection control. In: Mayall, CG, ed. Resistant Staphylococcus aureus in hospital epidemiology and infection control. 2nd ed. Philadelphia: Lippincott, Williams & Wilkins; 2003.
32.Mehta, S, Hill, NS. Noninvasive ventilation. Am J Respir Crit Care Med 2001;163:540577.
33.Davis, KA, Stewart, JJ, Crouch, HK, Florez, CE, Hospenthal, DR. Methicillin-resistant Staphylococcus aureus (MRSA) nares colonization at hospital admission and its effect on subsequent MRSA infection. Clin Infect Dis 2004; 39:776782.
34.Vierti, NJ, Dooley, DP, Davis, CE, Longfield, JN, Meier, PA, Whelen, AC. The effect of moving to a new hospital facility on the prevalence if methicillin resistant Staphylococcus aureus. Am J Infect Control 2004; 32: 262267.
35.Frank, MO, Battieger, BE, Sorensen, SJ, et al. Decrease in expenditures and select nosocomial infections following implementation of an antimicrobial-prescribing improvement program. Clin Perform Qual Health Care 1997; 5:180188.
36.Landman, D, Chockalingham, M, Quale, JM. Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae flowing changes in a hospital antibiotic formulary. Clin Infect Dis 1999; 28:10621066.
37.May, AK, Melton, SM, McGwin, G, Cross, JM, Mose, SA, Rue, LW. Reduction of vancomycin-resistant enterococcal infections by limitation of broad-spectrum cephalosporin use in a trauma and burn intensive care unit. Shock 2000; 14:259264.
38.Charbonneau, P, Thibon, JJ, Parienti, MJ, et al. Impact of a 12-month fluoroquinolone restriction on MRSA incidence in a French university hospital. In: Program and abstracts of the 43rd Annual Meeting of the Interscience Conference of Antimicrobial Chemotherapy; 2003; Chicago, IL. Abstract K-1743.
39.Schwaber, MJ, Cosgrove, SE, Gold, H, Kaye, KS, Carmeli, Y. Fluoroquinolones protective against cephalosporin resistance in gram-negative nosocomial pathogens. Emerg Infect Dis 2004; 10:9499.
40.Bisognano, C, Vaudaux, PE, Lew, DP, Ng, EY, Hooper, DC. Increased expression of fibronectin-binding proteins by fluoroquinolone-resistant Staphylococcus aureus exposed to subinhibitory levels of ciprofloxacin. Antimicrob Agents Chemother 1997; 41:906913.
41.Evans, ME, Titlow, WB. Levofloxacin selects fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus less frequently than ciprofloxacin. J Antimicrob Chemother 1998; 41:285288.

Related content

Powered by UNSILO

Evaluation of an Intervention Designed to Decrease the Rate of Nosocomial Methicillin-Resistant Staphylococcus aureus Infection by Encouraging Decreased Fluoroquinolone Use

  • Karl J. Madaras-Kelly (a1), Richard E. Remington (a2), Pamela G. Lewis (a3) and Dennis L. Stevens (a3) (a4)


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.